Compare Adaptive Biotechnologies Corp (ADPT) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Robinhood Markets, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $24.94 (market cap $4.04B), while Robinhood Markets, Inc. trades at $95.12 (market cap $84.86B). The key difference: Robinhood Markets, Inc. is far larger — about 21× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Robinhood Markets, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | HOOD | |
|---|---|---|
Market Cap | $4.04B | $84.86B |
Sector | Health | Technology |
52-Week High | $25.45 | $152.46 |
52-Week Low | $12.30 | $65.16 |
Enterprise Value | $4.10B | $91.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Robinhood Markets (HOOD) trades at $94.40, down 0.13% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust Q2 2026 results with revenue growth of 32% and earnings beating expectations, driven by diversification beyond crypto into event contracts and international expansion. Valuation metrics remain elevated with P/E of 41.76 and P/S of 17.6, reflecting premium pricing for growth prospects.
The outlook remains positive with analyst consensus pointing to significant upside (target $123.46), though near-term technical weakness and competitive pressures in the UK crypto expansion present risks. Revenue diversification and strong cash flow generation support long-term growth, but investors should monitor execution on international expansion and margin sustainability amid high valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
